Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

NovoCure Q3 2026 Results: Net Loss of $10.4M, Loss Narrows

For the nine months ended September 30, 2026, NovoCure reported net revenues of $551.0 million, a 14.6% increase compared to the same period in 2025. Despite the revenue growth, the company recorded a net loss of $97.2 million for the first nine months of 2026, though this was an improvement from the $111.7 million net loss in the prior year period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue193.4167.2
Gross profit148.9122.5
Profit before tax-7.9-30.0
Net income-10.4-37.3
EPS (diluted, $ a share)$-0.09$-0.33

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+15.7%
Gross margin77.0%
Operating margin-3.2%
Source

10-Q filed with the SEC, NASDAQ: NVCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

NovoCure Ltd: key numbers

Share price
$11.30Close, Nov 16
Market cap
$1.32B
Shares outstanding
116.92MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from NovoCure Ltd

All →
4:09 PM ET Form 4
Insider Selling

NovoCure COO Mukund Paravasthu Sells $39.6K of Stock

Mukund Paravasthu, COO, sold 3,079 shares of NovoCure Ltd at $12.86 a share, worth $39.6K in total on Nov 9, 2026. Shares held after the trade: 69,753 (-4.2%).

Value
$39.6K
Shares
3,079
Price
$12.86
Role
COO
Holding change
-4.2%
Trade date
Nov 9, 2026
4:09 PM ET Form 4
Insider Selling

NovoCure CFO Christoph Brackmann Sells $94.4K of Stock

Christoph Brackmann, CFO, sold 7,343 shares of NovoCure Ltd at $12.86 a share, worth $94.4K in total on Nov 9, 2026. Shares held after the trade: 175,499 (-4.0%).

Value
$94.4K
Shares
7,343
Price
$12.86
Role
CFO
Holding change
-4.0%
Trade date
Nov 9, 2026
7:00 AM ET 8-K
Business Update

NovoCure Business Update

NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.

7:01 AM ET 8-K
Financial Results

NovoCure Financial Results

Novocure reported record third-quarter net revenues of $193.4 million, a 16% year-over-year increase driven by 19% growth in active patients. The company significantly narrowed its net loss to $10.4 million and raised its full-year 2026 revenue and adjusted EBITDA guidance based on strong commercial performance.

Term
Q3 2026

“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies.”

Frank Leonard, CEO, Novocure

“We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”

Frank Leonard, CEO, Novocure
9:01 AM ET 8-K
Regulatory Approval

NovoCure Regulatory Approval

NovoCure received approval from Japan's Ministry of Health, Labour and Welfare for its Optune Pax device to treat adult patients with unresectable locally advanced pancreatic cancer. The approval was based on Phase 3 PANOVA-3 trial results showing statistically significant improvement in median overall survival. This marks a major commercial milestone for the company in Japan, where pancreatic cancer is the fourth leading cause of cancer death.

Counterparty
Ministry of Health, Labour and Welfare (MHLW)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.